Citi Maintains Buy on BioNTech (BNTX) Despite BNT113 Trial Setba
Citi maintains a Buy rating and $125 price target for BioNTech (BNTX) despite the BNT113 trial failing to meet its primary endpoint. The company's P/S ratio is 7.09, above its historical median, and its GF Score™ is 63. Insider selling totaled $89.8 million over the past year.
How this was made
The 30-second read
Why it matters
Citi’s reaffirmation and $125 target provide a near-term sentiment floor, but the failed endpoint is still a fundamental negative for the oncology pipeline narrative.
Market read
Traders get an analyst decision anchored to newly reported clinical trial disappointment, useful for positioning around sentiment but not a new fundamental inflection beyond the trial outcome.
What to watch
The article notes room for overall survival, but it does not provide OS results; traders may discount the OS possibility until data are actually reported.
Background
BioNTech’s BNT113 trial combined BNT113 with Merck’s pembrolizumab for head and neck squamous cell carcinoma and missed the primary endpoint on progression-free survival.
Ticker impact
Citi reaffirmed a Buy rating and set a $125 price target for BioNTech after BNT113 failed to improve progression-free survival in HNSCC.
Likely modest support as the market weighs the failed endpoint against the maintained Buy and unchanged target.
The article is an analyst reiteration tied to new trial results, but it does not introduce new trial positives or new company guidance beyond the rating/target.
Market effects
Reinforces that oncology immunotherapy combinations can fail on progression-free survival, keeping biotech risk premia elevated for similar programs.
Limited, as the catalyst is company-specific and the rating is from a US bank.
Moderate for global biotech sentiment, but not a broad sector shock.
Counterpoint
A maintained Buy after a failed primary endpoint can be a sign the market may still re-rate the pipeline risk downward, making the target less protective than it appears.
Key entities
- companyBioNTech SE
NASDAQ-listed biotech whose BNT113 trial results prompted Citi to reaffirm Buy and a $125 price target.
- clinical_programBNT113
BioNTech immunotherapy candidate evaluated in combination with pembrolizumab in HNSCC.
- drugpembrolizumab
Merck’s PD-1 therapy used in the trial combination.
